Other immunostimulants (local classification)
ATC code: L03AX-POLYOXIDONIUM (Azoximer bromide (Polyoxidonium) – local code)
The manufacturer claims immunomodulatory, antioxidant, and membrane-stabilizing effects from a synthetic polymer of N-oxidized polyethylenepiperazine. Marketed for infections, immunodeficiency, allergy, and as adjunctive cancer therapy. The molecule is not described as a therapeutic agent in international pharmacological literature. The 2020 claim of «efficacy in COVID-19» was not replicated in independent international RCTs. The Therapeutics and COVID-19 Living Guideline does not mention the drug.
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
Not recommended
Polyoxidonium for viral URI and influenza in adults and children is not mentioned in international guidelines. , , , and do not include it in viral infection standards. Standard URI care is symptomatic. Influenza-specific therapy: neuraminidase inhibitors (, zanamivir) and baloxavir; for COVID-19: nirmatrelvir/ in high-risk outpatients.
Sources
Not recommended
Polyoxidonium for allergic rhinitis is not mentioned in ARIA or guidelines. Evidence-based therapy: intranasal corticosteroids and second-generation H1 antagonists (loratadine, cetirizine), montelukast in severe cases, and allergen-specific immunotherapy in persistent disease.
Not recommended
Polyoxidonium (azoximer bromide), marketed by Petrovax, is positioned as a universal immunomodulator across a broad range of infections, allergies, and postoperative settings. The , , and AEMPS have not approved the drug; international clinical guidelines (, , ) do not include it. No independent international clinical studies with endpoints exist. If Polyoxidonium was recommended, consider seeking a second opinion.
Not recommended
Use of polyoxidonium as an «immunomodulator» for URI prevention in frequently ill children and adults is not supported by international guidelines. Proven preventive measures: vaccination (flu, pneumococcus, COVID-19), hand hygiene, ventilation, and masking during epidemics.
Not recommended
Polyoxidonium for COVID-19 is not mentioned in the Therapeutics and COVID-19 Living Guideline or NIH COVID-19 Treatment Guidelines. In hospitalized patients with hypoxemia, evidence-based therapies include dexamethasone, remdesivir, and tocilizumab in specific groups. In high-risk outpatients: nirmatrelvir/ritonavir within the first 5 days.
Sources
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Contraindicated in pregnancy per manufacturer label. No international recommendations.
Contraindicated during breastfeeding per manufacturer label.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Azoximer bromide is evaluated for the following indications with varying evidence strength: Acute respiratory viral infection (evidence tier F), Prophylaxis of acute respiratory infections (evidence tier F), Severe COVID-19 with hypoxia (evidence tier F). See the full indication matrix with dosing and citations above on this page.
Common side effects of Azoximer bromide (≥ 1 in 100): Pain and redness at the injection site, Allergic reactions (rare). See the Safety section for uncommon and serious reactions.
FDA category N. Contraindicated in pregnancy per manufacturer label. No international recommendations.
Contraindicated during breastfeeding per manufacturer label.
Azoximer bromide is contraindicated in: Pregnancy; Breastfeeding; Age under 6 months; Hypersensitivity. Full list in the Safety section.
the notion of a generic «immune system» liftable by a single tablet or injection does not align with modern immunology. Most frequently ill children and adults face high exposure in groups, poor sleep, or vitamin D deficiency — rarely true immunodeficiency, which requires specialist workup.
URI is self-limited and lasts 5–10 days regardless of polyoxidonium use. International guidelines do not support any 'immunomodulators' in URI.